These findings indicated the supplementation of TGF-β1 (or drugs that induced the increase of TGF-β1) may be an underlying approach for prevention and alleviation of AF cell loss and subsequent development and progression of IVDD and LBP in clinic. This evidence concerns the gene TGFB1 and atrial fibrillation.